ArticleJournal of clinical and translational hepatology2022

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?

Dimitrios Patoulias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.